Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering May 6, 2025
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback May 1, 2025
